TEL AVIV, Israel and BETHESDA, Maryland, Aug. 2, 2018 /PRNewswire/ —
Dear Fellow Shareholders,
I am pleased to announce that we have entered the second half of 2018 with strong momentum. Now that we have officially moved into our new state-of-the-art Cancer Screening Laboratory located in Rehovot, Israel we are poised for symbiotic scientific partnerships.
Both the company and our new Laboratory are broadly licensed by the Ministry of Health in Israel specifically for R&D on Cannabis. We see great potential in scientific collaborations with like-minded companies that are engaged in cannabinoid medicines and diagnostics. Currently, we are in the final stages of finalizing our agreement with a company engaged in ophthalmic disorders to develop a product to compete with Steroids in the ocular disease market.
Our team of scientists are diligently working to develop and expand our intellectual property portfolio. As such we are waiting for numerous approvals from various national level registrations on our Cannabinoid – Cancer screening patents.
The company is anticipating the final report from Prof. Gil Bar-Sela of Rambam Hospital from its clinical trial on cancer patients of our SR capsule for Cachexia and Anorexia, which is expected to be presented in the coming weeks/months. Dr. Bar-Sela is the Deputy Director of the Division of Oncology at Rambam Health Care Campus, Head of the Palliative and Supportive Oncology Unit, and Head of the service for Melanoma and Sarcoma patients.
Our Marketing PR/IR Team is in the process of rolling out new updated informational materials to give the public more insight into our current activities. An essential part of this effort is the process of revamping our website with much more detailed content and information alongside an extensive Investor Relations section. Some of these changes have already taken effect and we expect more to follow suit shortly. We are making a concerted effort to bring our message to light and tell our story to the world, as we are passionate about what we do, and want to spread that passion.
In the recent months, we have received significant media coverage.
Some select recent interviews:
a. Scientific American – Published on May 2, 2018 – Cannabis versus Cancer
b. The Pot Network – Published on July 11, 2018 – The Consumption of Cannabis As A Medicine For Cancer: An Exclusive Interview With Cannabics Pharmaceuticals CEO Eyal Barad
c. Benzinga Online – Published on July 13, 2018 – 4 Questions With Cannabics Pharmaceuticals CEO Eyal Barad
We feel privileged to be able to do such important Government licensed R&D on Cannabinoids, where several years ago we would have been prevented from doing so by regulation. Look out for more news from us and sign up to our newsletter.
Cannabics Pharmaceuticals prides itself as being at the forefront of integrating cannabinoids into modern precision medical care, creating disruptive, cannabinoid-based personalized medical technologies and introducing new ways of thinking of treatment to the world. Please sign up to join us.
Eyal Barad, CEO
(The company’s updated presentation is now available on the website)
About Cannabics Pharmaceuticals Inc.
Cannabics Pharmaceuticals Inc. (OTC: CNBX) is a United States listed public company that is developing cannabinoid diagnostic tests for the personalized treatment of cancer. Cannabics is licensed by the Israeli Ministry of Health for Cannabinoid research, and is currently developing a blood test that allows practitioners to precisely tailor medical cannabinoid-based therapies to an individual patient’s profile and cancer. Cannabics’ approach can also be used to develop cannabinoid-based therapies as preventive or primary cancer treatments – not just palliative. By developing tools to assess effectiveness on a personalized basis, Cannabics is helping to move medical cannabinoids into the mainstream of cancer therapies.
Certain statements contained in this release constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to statements identified by words such as “believes,” “expects,” “anticipates,” “estimates,” “intends,” “plans,” “targets,” “projects” and similar expressions. The statements in this release are based upon the current beliefs and expectations of our company’s management and are subject to significant risks and uncertainties. Actual results may differ from those set forth in the forward-looking statements. Numerous factors could cause or contribute to such differences, including, but not limited to, results of clinical trials and/or other studies, the challenges inherent in new product development initiatives, the effect of any competitive products, our ability to license and protect our intellectual property, our ability to raise additional capital in the future that is necessary to maintain our business, changes in government policy and/or regulation, potential litigation by or against us, any governmental review of our products or practices, as well as other risks discussed from time to time in our filings with the Securities and Exchange Commission, including, without limitation, our latest 10-Q Report filed on July 16th, 2018. We undertake no duty to update any forward-looking statement or any information contained in this press release or in other public disclosures at any time.